New Publication Validates StemCells, Inc.'s SC Proven(R) Reagents for Automated Production and Cell-Based Screening
July 22 2011 - 9:00AM
StemCells, Inc. (Nasdaq:STEMD) announced today publication of a
collaborative study which used commercially available SC Proven
serum-free cell culture media for the reproducible and robust
production of large numbers of genetically stable, self-renewing
cells that retain true multi-potent biological function over
extended culture periods. This work overcomes a key hurdle to the
use of non-immortalized cells for regenerative medicine, and
demonstrates the utility of human tissue-derived neural stem (NS)
cells1 as a scalable platform for cell-based drug discovery and
drug screening applications. The paper was published in a special
edition of Neurochemistry International dedicated to "The Potential
of Stem Cells for 21st Century Neuroscience" and is available
online at
http://www.sciencedirect.com/science/article/pii/S0197018611002452
"We can now say our serum-free RHB-A® and RHB-Basal® culture
media are 'Automation Proven' for large-scale production of
billions of stem cells per week for regenerative medicine
applications," said Stewart Craig, Ph.D., Senior Vice President,
Development & Operations at StemCells, Inc. "This work by our
scientists and their collaborators underscores the rationale for,
and the advantage of, using well-defined, serum-free and where
possible animal component-free reagents for cell culture and
cell-based assays because it eliminates contaminants that cause
culture variability and that impair assay performance."
Furthermore, Hook et al used the CompacT SelecT™ system from TAP
Biosystems for the at scale automated dispensing of NS cells into
multi-well plates with onward incubation for in vitro cell-based
drug screening assays. These assays also used the serum-free RHB-A
and RHB-Basal culture media along with the serum-free and animal
component-free NDiff® N2-AF and NDiff® N27-AF culture supplements.
This newly reported data adds to that previously presented by the
Company at international regenerative medicine and drug screening
meetings2,3 in which the same SC Proven reagents were used for the
automated scale-up, production and assay screening of human induced
pluripotent stem (iPS) cell-derived NS cell lines.
The tools and technologies showcased in this work are components
of the platform that StemCells has integrated to help partners
address all phases of drug discovery and development, from initial
screening through in vitro characterization, and then in vivo
validation of lead candidates using the actual human target cell
(http://www.stemcellsinc.com/Tools-and-Technologies/Drug-Discovery-and-Development.htm).
A comprehensive overview of the Company's drug discovery platform
was presented last month at the 12th Drug Discovery Leaders Summit
in Zurich, Switzerland.
References
- Hook L, et al., Non-immortalized Human Neural Stem (NS) Cells
as a Scalable Platform for Cellular Assays. (2011) Neurochemistry
International doi: 10.1016/j.neuint.2011.06.024
- "Platform Solutions for Stem Cell-based Drug Discovery"
presented at the Terrapinn "World Stem Cells &
Regenerative Medicine Conference" in London, UK, May 2010
- "Platform Solutions for Stem Cell-based Drug Discovery"
presented at the Select Biosciences "Stem Cells Europe" meeting in
Edinburgh, UK, August 2010
About SC Proven Products
The SC Proven product portfolio comprises a range of products
for the detection, isolation, expansion, differentiation, and
characterization of a variety of different human and animal cell
types. The entire SC Proven product catalog and online
ordering can be found at www.scproven.com.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and
commercialization of cell-based therapeutics and tools for use in
stem cell-based research and drug discovery. The Company's lead
therapeutic product candidate, HuCNS-SC® cells (purified human
neural stem cells), is currently in development as a potential
treatment for a broad range of central nervous system
disorders. Clinical trials are currently underway in spinal
cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children. In addition, the Company
plans to file an IND by year-end 2011 to initiate a clinical trial
of HuCNS-SC cells in age-related macular degeneration, and is also
pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's
disease and stroke. StemCells also markets stem cell research
products, including media and reagents, under the SC Proven®brand,
and is developing stem cell-based assay platforms for use in
pharmaceutical research, drug discovery and drug development.
Further information about StemCells is available at
http://www.stemcellsinc.com.
The StemCells, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7014
Apart from statements of historical fact, the text of this press
release constitutes forward-looking statements within the meaning
of the U.S. securities laws, and is subject to the safe harbors
created therein. These statements include, but are not limited to,
statements regarding the prospect of continued growth of the
Company's SC Proven reagents business; the potential regulatory
acceptability of cell culture supplements used to derive cells for
human research; clinical development of the Company's HuCNS-SC
cells; the prospects for the Company to pursue non-therapeutic
applications of its cell-based technologies; and the future
business operations of the Company. These forward-looking
statements speak only as of the date of this news release. The
Company does not undertake to update any of these forward-looking
statements to reflect events or circumstances that occur after the
date hereof. Such statements reflect management's current views and
are based on certain assumptions that may or may not ultimately
prove valid. The Company's actual results may vary materially from
those contemplated in such forward-looking statements due to risks
and uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2010, and in
its subsequent reports on Form 8-K.
CONTACT: Rodney Young
Chief Financial Officer
(510) 456-4128
Stemcells, Inc. (MM) (NASDAQ:STEMD)
Historical Stock Chart
From May 2024 to Jun 2024
Stemcells, Inc. (MM) (NASDAQ:STEMD)
Historical Stock Chart
From Jun 2023 to Jun 2024